» Articles » PMID: 38864106

Incidence and Management of the Main Serious Adverse Events Reported After COVID-19 Vaccination

Overview
Date 2024 Jun 12
PMID 38864106
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2n first appeared in Wuhan, China in 2019. Soon after, it was declared a pandemic by the World Health Organization. The health crisis imposed by a new virus and its rapid spread worldwide prompted the fast development of vaccines. For the first time in human history, two vaccines based on recombinant genetic material technology were approved for human use. These mRNA vaccines were applied in massive immunization programs around the world, followed by other vaccines based on more traditional approaches. Even though all vaccines were tested in clinical trials prior to their general administration, serious adverse events, usually of very low incidence, were mostly identified after application of millions of doses. Establishing a direct correlation (the cause-effect paradigm) between vaccination and the appearance of adverse effects has proven challenging. This review focuses on the main adverse effects observed after vaccination, including anaphylaxis, myocarditis, vaccine-induced thrombotic thrombocytopenia, Guillain-Barré syndrome, and transverse myelitis reported in the context of COVID-19 vaccination. We highlight the symptoms, laboratory tests required for an adequate diagnosis, and briefly outline the recommended treatments for these adverse effects. The aim of this work is to increase awareness among healthcare personnel about the serious adverse events that may arise post-vaccination. Regardless of the ongoing discussion about the safety of COVID-19 vaccination, these adverse effects must be identified promptly and treated effectively to reduce the risk of complications.

Citing Articles

Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.

Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T Vaccines (Basel). 2024; 12(9).

PMID: 39340089 PMC: 11435548. DOI: 10.3390/vaccines12091059.


An improvement of the safety profile of SARS-CoV-2 vaccines is desirable.

Finsterer J Pharmacol Res Perspect. 2024; 12(5):e70008.

PMID: 39263854 PMC: 11391212. DOI: 10.1002/prp2.70008.


Incidence and management of the main serious adverse events reported after COVID-19 vaccination.

Padilla-Flores T, Sampieri A, Vaca L Pharmacol Res Perspect. 2024; 12(3):e1224.

PMID: 38864106 PMC: 11167235. DOI: 10.1002/prp2.1224.

References
1.
Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi S, Razvi S . Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021; 27(12):2144-2153. PMC: 8629105. DOI: 10.1038/s41591-021-01556-7. View

2.
Ostovan V, Sahraian M, Karazhian N, Rostamihosseinkhani M, Salimi M, Marbooti H . Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic review. Mult Scler Relat Disord. 2022; 66:104032. PMC: 9258415. DOI: 10.1016/j.msard.2022.104032. View

3.
Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y . Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021; 385(23):2132-2139. PMC: 8531986. DOI: 10.1056/NEJMoa2110737. View

4.
Buoninfante A, Andeweg A, Baker A, Borad M, Crawford N, Dogne J . Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. NPJ Vaccines. 2022; 7(1):141. PMC: 9643955. DOI: 10.1038/s41541-022-00569-8. View

5.
Gao J, Feng L, Li Y, Lowe S, Guo Z, Bentley R . A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis. Am J Prev Med. 2022; 64(2):275-284. PMC: 9510095. DOI: 10.1016/j.amepre.2022.09.002. View